CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea
Da Hea Seo, Kyoung Hwa Ha, So Hun Kim, Dae Jung Kim
Endocrinol Metab. 2021;36(1):70-80.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.777

Excel Download

Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea
Endocrinology and Metabolism. 2021;36(1):70-80   Crossref logo
Link1 Link2 Link3

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2016;Volume 9:347-353   Crossref logo
Link1 Link2

QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2)
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(5):102264   Crossref logo
Link1 Link2

993-P: A Real-World New User Cohort Study of Metformin vs. SGLT2i or GLP-1RA on the Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients with Cardiovascular Risk Factors
Diabetes. 2021;70(Supplement 1):993-P   Crossref logo
Link1

Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience
Journal of Diabetes Mellitus. 2018;08(04):152-159   Crossref logo
Link1 Link2

Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
Diabetes Therapy. 2014;5(2):579-590   Crossref logo
Link1 Link2 Link3 Link4

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
Journal of Lipid and Atherosclerosis. 2021;10(2):210   Crossref logo
Link1 Link2 Link3

Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)
Diabetes Therapy. 2020;11(10):2257-2268   Crossref logo
Link1 Link2 Link3

Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira : A real‐world, population‐based cohort study
Diabetes, Obesity and Metabolism. 2021;   Crossref logo
Link1 Link2 Link3

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
Diabetes mellitus. 2011;14(3):111-112   Crossref logo
Link1 Link2